XML 45 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Equity Incentive Plans (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Jan. 20, 2017
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Options        
Outstanding balance at the beginning of the period (in shares)   8,525,618    
Granted (in shares)   650,000    
Forfeited (in shares)   (74,111)    
Outstanding balance at the end of the period (in shares)   9,101,507   8,525,618
Options exercisable at the end of the period (in shares)   5,983,001    
Options vested and expected to vest at end of period (in shares)   9,101,507    
Weighted Average Exercise Price Per Share        
Outstanding balance at the beginning of the period (in dollars per share)   $ 4.48    
Granted (in dollars per share)   1.97    
Forfeited (in dollars per share)   2.11    
Outstanding balance at the end of the period (in dollars per share)   4.32   $ 4.48
Exercisable at the end of the period (in dollars per share)   5.48    
Options vested and expected to vest at end of the period (in dollars per share)   $ 4.32    
Weighted Average Remaining Life in Years        
Outstanding balance   7 years 5 months 12 days   7 years 6 months 29 days
Options exercisable at end of period   6 years 8 months 23 days    
Options vested and expected to vest at end of the period   7 years 5 months 12 days    
Aggregate Intrinsic Value        
Outstanding balance   $ 697   $ 7,673
Options exercisable at the end of the period   514    
Options vested and expected to vest at end of the period   $ 697    
Assumptions used to determine grant-date fair value        
Expected Volatility   82.70% 66.94%  
Weighted average risk-free interest rate   1.67% 0.66%  
Expected dividend yield   0.00% 0.00%  
Expected term (in years)   6 years 3 days 6 years 10 months 9 days  
Expiration period   10 years    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value   $ 1.39 $ 1.57  
Compensation cost related to the non-vested awards not yet recognized   $ 3,901    
Weighted average period for recognition of compensation cost   1 year 9 months 25 days    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Outstanding at end(in dollars per share)   $ 1.39 $ 1.57  
Minimum        
Assumptions used to determine grant-date fair value        
Vesting period   3 years    
Maximum        
Assumptions used to determine grant-date fair value        
Vesting period   4 years    
2016 Plan        
Assumptions used to determine grant-date fair value        
Annual increase in authorized shares (as a percent) 4.00%      
Number of options or stock awards available for grant under the Plan   791,745    
Options to purchase common stock        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Stock-based compensation expense   $ 1,204 $ 833  
Options to purchase common stock | Research and development        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Stock-based compensation expense   554 345  
Options to purchase common stock | General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Stock-based compensation expense   650 $ 488  
Restricted stock units to purchase common stock        
Assumptions used to determine grant-date fair value        
Aggregate grant fair value   6,640    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount   $ 5,452    
Weighted average period for recognition of compensation cost   2 years 7 months 28 days    
Restricted stock units to purchase common stock | Executive Officer [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]        
Awarded   2,575,000 275,000  
Restricted stock units to purchase common stock | 2016 Plan        
Assumptions used to determine grant-date fair value        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value   $ 1.89   $ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]        
Outstanding at the beginning   935,606 753,106 753,106
Awarded   2,575,000   275,000
Settled in cash       (92,500)
Outstanding at the end   3,510,606   935,606
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Outstanding at beginning( in dollars per share)   $ 1.76 $ 1.52 $ 1.52
Awarded (in dollars per share)   1.94   2.57
Settled in cash(in dollars per share)       1.97
Outstanding at end(in dollars per share)   $ 1.89   $ 1.76